Health Care & Life Sciences » Biotechnology | AC Immune

AC Immune S.A. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
33,066.00
40,597.00
23,563.50
20,578.90
7,350.80
SG&A Expense
21,033.10
20,956.90
33,894.80
42,889.00
56,999.20
EBIT
11,707.30
19,342.00
10,613.40
22,899.40
50,630.30
Non Operating Income/Expense
4.40
27.00
259.90
4,120.90
1,156.70
Pretax Income
11,736.80
21,051.40
7,202.80
26,833.30
52,061.90
Consolidated Net Income
11,736.80
21,051.40
7,202.80
26,833.30
52,061.90
Net Income
11,736.80
21,051.40
7,202.80
26,833.30
52,061.90
Net Income After Extraordinaries
11,736.80
21,051.40
7,202.80
26,833.30
52,061.90
Net Income Available to Common
11,736.80
21,051.40
7,202.80
26,833.30
52,061.90
EPS (Basic)
68.75
0.49
0.14
0.47
0.84
Basic Shares Outstanding
170.70
43,412.30
50,096.90
57,084.30
61,838.20
EPS (Diluted)
64.41
0.46
0.14
0.47
0.84
Diluted Shares Outstanding
182.20
46,043.20
50,096.90
57,084.30
61,838.20
EBITDA
12,032.80
19,640.00
10,331.20
22,310.10
49,648.40
Non-Operating Interest Income
33.90
1,736.50
3,670.40
186.90
29.60

About AC Immune

View Profile
Address
EPFL Innovation Park
Lausanne Basel-Landschaft (Basle Country) 1015
Switzerland
Employees -
Website http://www.acimmune.com
Updated 07/08/2019
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.